Phase 2 Lymphoma Trial, Recruiting (NCT06664411)

Phase 2 Lymphoma Trial, Recruiting NCT06664411 Sponsor: Navy General Hospital, Beijing Condition: Lymphoma

Printed from Voxsanity (voxsanity.com.au) — NCT06664411 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lymphoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with Diffuse Large B Cell Lymphoma (a type of blood cancer), confirmed by laboratory testing according to international medical guidelines
People who are 18 years of age or older at the time of signing the consent form
People who are able to understand and are willing to sign a consent form before any trial-related tests or procedures begin
People who are willing and able to attend scheduled trial visits and follow the trial's requirements
People who have never previously received chemotherapy
People who are expected to live for at least 3 months

Who may not be able to join:

People who have an active or uncontrolled infection that requires medication or treatment within 14 days before enrolling in the trial
People who have an unstable serious illness affecting the heart, liver, kidneys, or body's metabolic system that requires ongoing treatment
People who are pregnant or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Liren Qian, PhD, Navy General Hospital, Beijing

Phone: +861066947194

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06664411

Sponsor: Navy General Hospital, Beijing

Phase: Phase 2

Status: Recruiting

Condition: Lymphoma

Trial contact: +861066947194

More information: https://clinicaltrials.gov/study/NCT06664411

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with Diffuse Large B Cell Lymphoma (a type of blood cancer), confirmed by laboratory testing according to international medical guidelines
People who are 18 years of age or older at the time of signing the consent form
People who are able to understand and are willing to sign a consent form before any trial-related tests or procedures begin
People who are willing and able to attend scheduled trial visits and follow the trial's requirements
People who have never previously received chemotherapy
People who are expected to live for at least 3 months

Who may not be able to join:

People who have an active or uncontrolled infection that requires medication or treatment within 14 days before enrolling in the trial
People who have an unstable serious illness affecting the heart, liver, kidneys, or body's metabolic system that requires ongoing treatment
People who are pregnant or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Navy General Hospital, Beijing

Registry

ClinicalTrials.gov

Start date

24 September 2024

Est. completion

1 December 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression Free Survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov